Logo image of PTP.DE

PENTIXAPHARM HOLDING AG (PTP.DE) Stock Fundamental Analysis

Europe - FRA:PTP - DE000A40AEG0 - Common Stock

1.546 EUR
+0.05 (+3.34%)
Last: 11/7/2025, 7:00:00 PM
Fundamental Rating

2

Overall PTP gets a fundamental rating of 2 out of 10. We evaluated PTP against 60 industry peers in the Health Care Equipment & Supplies industry. While PTP has a great health rating, there are worries on its profitability. PTP does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PTP has reported negative net income.
PTP.DE Yearly Net Income VS EBIT VS OCF VS FCFPTP.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2024 0 5M -5M -10M

1.2 Ratios

PTP's Return On Assets of -41.54% is on the low side compared to the rest of the industry. PTP is outperformed by 85.00% of its industry peers.
PTP has a Return On Equity of -51.74%. This is in the lower half of the industry: PTP underperforms 75.00% of its industry peers.
Industry RankSector Rank
ROA -41.54%
ROE -51.74%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PTP.DE Yearly ROA, ROE, ROICPTP.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2024 0 10 -10 -20

1.3 Margins

PTP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PTP.DE Yearly Profit, Operating, Gross MarginsPTP.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2024 0 100 -100

More info and screens

7

2. Health

2.1 Basic Checks

PTP does not have a ROIC to compare to the WACC, probably because it is not profitable.
PTP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PTP.DE Yearly Shares OutstandingPTP.DE Yearly Shares OutstandingYearly Shares Outstanding 2024 5M 10M 15M 20M
PTP.DE Yearly Total Debt VS Total AssetsPTP.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2024 20M 40M 60M

2.2 Solvency

PTP has an Altman-Z score of 1.37. This is a bad value and indicates that PTP is not financially healthy and even has some risk of bankruptcy.
PTP has a Altman-Z score of 1.37. This is in the lower half of the industry: PTP underperforms 68.33% of its industry peers.
There is no outstanding debt for PTP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.37
ROIC/WACCN/A
WACC7.33%
PTP.DE Yearly LT Debt VS Equity VS FCFPTP.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2024 0 10M 20M 30M 40M

2.3 Liquidity

PTP has a Current Ratio of 2.56. This indicates that PTP is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of PTP (2.56) is better than 71.67% of its industry peers.
A Quick Ratio of 2.56 indicates that PTP has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 2.56, PTP belongs to the best of the industry, outperforming 85.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.56
Quick Ratio 2.56
PTP.DE Yearly Current Assets VS Current LiabilitesPTP.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2024 10M 20M 30M

More info and screens

0

3. Growth

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PTP.DE Yearly Revenue VS EstimatesPTP.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2M 4M 6M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PTP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PTP.DE Price Earnings VS Forward Price EarningsPTP.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PTP.DE Per share dataPTP.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PTP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PENTIXAPHARM HOLDING AG

FRA:PTP (11/7/2025, 7:00:00 PM)

1.546

+0.05 (+3.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners5.42%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap38.34M
Revenue(TTM)6.86M
Net Income(TTM)-21.22M
Analysts80
Price Target11.95 (672.96%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.59
P/FCF N/A
P/OCF N/A
P/B 0.93
P/tB 5.55
EV/EBITDA N/A
EPS(TTM)-0.69
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.28
BVpS1.65
TBVpS0.28
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -41.54%
ROE -51.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.56
Quick Ratio 2.56
Altman-Z 1.37
F-ScoreN/A
WACC7.33%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

PENTIXAPHARM HOLDING AG / PTP.DE FAQ

What is the ChartMill fundamental rating of PENTIXAPHARM HOLDING AG (PTP.DE) stock?

ChartMill assigns a fundamental rating of 2 / 10 to PTP.DE.


What is the valuation status for PTP stock?

ChartMill assigns a valuation rating of 0 / 10 to PENTIXAPHARM HOLDING AG (PTP.DE). This can be considered as Overvalued.


How profitable is PENTIXAPHARM HOLDING AG (PTP.DE) stock?

PENTIXAPHARM HOLDING AG (PTP.DE) has a profitability rating of 0 / 10.